Guideline for collection, analysis and presentation of safety data in clinical trials of vaccines in pregnant women

Vaccine

Volumn 34, Issue 49, 2016, Pages 5998-6006

  Jones, Christine E ^a   Munoz, Flor M ^b   Spiegel, Hans M L ^c   Heininger, Ulrich ^d   Zuber, Patrick L F ^e   Edwards, Kathryn M ^f   Lambach, Philipp ^e   Neels, Pieter ^g   Kohl, Katrin S ^h   Gidudu, Jane ^h   Hirschfeld, Steven ⁱ   Oleske, James M ^j   Khuri Bulos, Najwa ^k   Bauwens, Jorgen ^l   Eckert, Linda O ^m   Kochhar, Sonali ⁿ   Bonhoeffer, Jan ^d   Heath, Paul T ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Henry Jackson Foundation   (United States)

^d UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^g International Alliance for Biological Standardization   (France)

^h CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

ⁱ EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^j RUTGERS UNIVERSITY   (United States)

^k UNIVERSITY OF JORDAN   (Jordan)

^l Brighton Collaboration Foundation   (Switzerland)

^m UNIVERSITY OF WASHINGTON   (United States)

ⁿ Global Healthcare Consulting   (India)

more..

Author keywords

Adverse event; Clinical trials; Guidelines; Immunization; Pregnancy; Safety; Vaccines

Indexed keywords

VACCINE;

ARTICLE; DATA ANALYSIS; DRUG SAFETY; FOLLOW UP; HUMAN; INFORMATION PROCESSING; LABORATORY TEST; MEDICAL ETHICS; NEWBORN DEATH; NUTRITIONAL STATUS; PRACTICE GUIDELINE; PREGNANT WOMAN; PRIORITY JOURNAL; PUBLIC HEALTH; RESTING HEART RATE; SYSTEMATIC REVIEW; VACCINATION; CLINICAL TRIAL (TOPIC); FEMALE; INFANT; PREGNANCY; PREGNANCY COMPLICATION; STATISTICS;

CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; INFANT; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; STATISTICS AS TOPIC; VACCINATION; VACCINES;

EID: 84997221726     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.07.032     Document Type: Article

References (55)

1. [1] Belizan, J.M., et al. Neonatal death in low- to middle-income countries: a global network study. Am J Perinatol 29:8 (2012), 649–656.
2. [2] Lawn, J., Hidden deaths of the world's newborn babies. Bull World Health Organ 86:4 (2008), 250–251.
3. [3] Jamieson, D.J., et al. Benefits of influenza vaccination during pregnancy for pregnant women. Am J Obstet Gynecol 207:Suppl. 3 (2012), S17–S20.
4. [4] Kourtis, A.P., Read, J.S., Jamieson, D.J., Pregnancy and infection. N Engl J Med 370:23 (2014), 2211–2218.
5. [5] Fox, K.A., Theiler, R., Vaccination in pregnancy. Curr Pharm Biotechnol 12:5 (2011), 789–796.
6. [6] Fell, D.B., et al. H1N1 influenza vaccination during pregnancy and fetal and neonatal outcomes. Am J Public Health 102:6 (2012), e33–e40.
7. [7] WHO, Tetanus vaccine. Wkly Epidemiol Rec 81:20 (2006), 198–208.
8. [8] Grohskopf, L.A., et al. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices (ACIP) – United States, 2014–15 influenza season. MMWR Morb Mortal Wkly Rep 63:32 (2014), 691–697.
9. [9] Ortiz, J.R., et al. Translating vaccine policy into action: a report from the Bill & Melinda Gates Foundation Consultation on the prevention of maternal and early infant influenza in resource-limited settings. Vaccine 30:50 (2012), 7134–7140.
10. [10] CDC, Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices (ACIP)—United States, 2014–15 influenza season. Morb Mortal Wkly Rep 63:32 (2014), 691–697.
11. [11] WHO, Vaccines against influenza WHO position paper – November 2012. Wkly Epidemiol Rec 47:87 (2012), 461–476.
12. [12] CDC, Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices (ACIP). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women – ACIP, 2012. MMWR Morb Mortal Wkly Rep 62:7 (2013), 131–135.
13. [13] NHS, Whooping cough vaccination in pregnancy. Available from: < http://www.nhs.uk/conditions/pregnancy-and-baby/pages/whooping-cough-vaccination-pregnant.aspx> [accessed August 31, 2015].
14. [14] Public Health Agency of Canada, Canadian immunization guide. Immunization in pregnancy and breastfeeding. Available from: < http://www.phac-aspc.gc.ca/publicat/cig-gci/p03-04-eng.php> [accessed August 31st, 2015].
15. [15] Australian Government Department of Health, The australian immunization handbook. Pertussis; 2015. Available from: < http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home~handbook10part4~handbook10-4-12> [accessed August 31st 2015].
16. [16] WHO, Pertussis vaccine: WHO position paper. Wkly Epidemiol Rec 85 (2010), 385–400.
17. [17] CDC. Guidelines for Vaccinating Pregnant Women; 2014. Available from: < http://www.cdc.gov/vaccines/pubs/preg-guide.htm> [accessed November 22nd 2015].
18. [18] Heath, P.T., An update on vaccination against group B streptococcus. Expert Rev Vaccines 10:5 (2011), 685–694.
19. [19] Munoz, F.M., Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?. Curr Opin Infect Dis 28:3 (2015), 221–224.
20. [20] Holmlund, E., et al. Mother-infant vaccination with pneumococcal polysaccharide vaccine: persistence of maternal antibodies and responses of infants to vaccination. Vaccine 29:28 (2011), 4565–4575.
21. [21] Chaithongwongwatthana, S., et al. Pneumococcal vaccination during pregnancy for preventing infant infection. Cochrane Database Syst Rev, 1, 2015, CD004903.
22. [22] The first international neonatal vaccination workshop; March 2–4, 2004. Available from: < http://www2a.cdc.gov/tceonline/registration/detailpage.asp?res_id=885>.
23. [23] Fondation Merieux, Maternal immunization: challenges and opportunities. 24–26 September 2012, Les Pensières, Annecy, France. Available from: < http://www.fondation-merieux.org/maternal-immunization>.
24. [24] Fulton, T.R., et al. A systematic review of adverse events following immunization during pregnancy and the newborn period. Vaccine, 2015.
25. [25] Amirthalingam, G., et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet 384:9953 (2014), 1521–1528.
26. [26] Donegan, K., King, B., Bryan, P., Safety of pertussis vaccination in pregnant women in UK: observational study. BMJ, 349, 2014, g4219.
27. [27] Heikkinen, T., et al. Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study. Am J Obstet Gynecol, 207(3), 2012 p. 177 e1–8.
28. [28] Madhi, S.A., et al. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med 371:10 (2014), 918–931.
29. [29] EMEA, Committee for medicinal products for human use (CHMP). Guideline on the exposure to medicinal products during pregnancy: need for post-authorisation data; 2005. Available from: < http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/11/WC500011303.pdf​​>.
30. [30] Roberts, J.N., Gruber, M.F., Regulatory considerations in the clinical development of vaccines indicated for use during pregnancy. Vaccine 33:8 (2015), 966–972.
31. [31] Ross, S.D., The CONSORT statement. JAMA, 276(23), 1996, 1877 author reply 1877.
32. [32] Reveiz, L., Krleza-Jeric, K., Consort 2010. Lancet, 376(9737), 2010, 230.
33. [33] Ioannidis, J.P., et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 141:10 (2004), 781–788.
34. [34] Bonhoeffer, J., et al. Guidelines for collection, analysis and presentation of vaccine safety data in pre- and post-licensure clinical studies. Vaccine 27:16 (2009), 2282–2288.
35. [35] Bonhoeffer, J., et al. Template protocol for clinical trials investigating vaccines–focus on safety elements. Vaccine 31:47 (2013), 5602–5620.
36. [36] Munoz, F.M., et al. Research on vaccines during pregnancy: protocol design and assessment of safety. Vaccine 31:40 (2013), 4274–4279.
37. [37] Sheffield, J.S., et al. Research on vaccines during pregnancy: reference values for vital signs and laboratory assessments. Vaccine 31:40 (2013), 4264–4273.
38. [38] Beigi, R.H., et al. Maternal immunization: opportunities for scientific advancement. Clin Infect Dis 59:Suppl. 7 (2014), S408–S414.
39. [39] Munoz, F.M., et al. Assessment of safety in newborns of mothers participating in clinical trials of vaccines administered during pregnancy. Clin Infect Dis 59:Suppl. 7 (2014), S415–S427.
40. [40] Brighton Collaboration. Data collection forms. Available from: < https://brightoncollaboration.org/public/resources/data-collection-forms.html>.
41. [41] Brighton Collaboration. Process. Available from: < https://brightoncollaboration.org/public/what-we-do/setting-standards/case-definitions/process.html>.
42. [42] Munoz, F.M., et al. Key terms for the assessment of the safety of vaccines in pregnancy: results of a global consultative process to initiate harmonization of adverse event definitions. Vaccine, 2015.
43. [43] Brighton Collaboration. Harmonizing safety assessment of immunization in pregnancy. Available from: < https://brightoncollaboration.org/public/resources/standards/case-definitions/pregnancy.html>.
44. [44] Brighton Collaboration. ABC tool Available from: < https://brightoncollaboration.org/public/resources/abc-tool.html>.
45. [45] van de Pavert, S.A., et al. Maternal retinoids control type 3 innate lymphoid cells and set the offspring immunity. Nature 508:7494 (2014), 123–127.
46. [46] Schaefer, C., Peters, P., Miller, R., Drugs during pregnancy and lactation. third ed., 2014, Academic Press.
47. [47] van Gelder, M.M., de Jong-van den Berg, L.T., Roeleveld, N., Drugs associated with teratogenic mechanisms. Part II: a literature review of the evidence on human risks. Hum Reprod 29:1 (2014), 168–183.
48. [48] WHO. Causality assessment of an adverse event following immunization (AEFI). User manual for the revised WHO AEFI causality assessment classification. Available from: < http://www.who.int/vaccine_safety/publications/gvs_aefi/en/>.
49. [49] Gidudu, J., et al. A local reaction at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 26:52 (2008), 6800–6813.
50. [50] Heininger, U., et al. The concept of vaccination failure. Vaccine 30:7 (2012), 1265–1268.
51. [51] Moher, D., Schulz, K.F., Altman, D.G., The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 357:9263 (2001), 1191–1194.
52. [52] Moher, D., et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 354:9193 (1999), 1896–1900.
53. [53] Des Jarlais, D.C., et al. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. Am J Public Health 94:3 (2004), 361–366.
54. [54] von Elm, E., et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61:4 (2008), 344–349.
55. [55] Stroup, D.F., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283:15 (2000), 2008–2012.